Alkem Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+13.5%+8.2%
EBITDA+19.6%+23.1%
Net Income+6.1%+32.7%
EPS (adj.)+6.3%+32.7%
Total Assets+18.0%+14.9%
Total Equity+15.4%+15.0%
Free Cash Flow+8.8%−2.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health
₹ CrorePeersMANKINDTORNTPHARMIPCALABLUPINFORTISAUROPHARMALAURUSLABSBIOCONMcap ₹60,719 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+13.5+8.2
EBITDA+19.6+23.1
Net Income+6.1+32.7
EPS (adj.)+6.3+32.7
Total Assets+18.0+14.9
Total Equity+15.4+15.0
Free Cash Flow+8.8-2.4
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.